Press Release: Basilea reports derazantinib/PD-L1 -2-

America 2018 (115), E4041-E4050

10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib

(ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive

intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120),

165-171. ClinicalTrials.gov identifier: NCT01752920

11. FIDES-03: ClinicalTrials.gov identifier: NCT04604132

Attachment

Press release (PDF)

https://www.globenewswire.com/Tracker?data=Gpyflbpji0yIeCQGU5M1iLk4IH_OdBusMeXdfyUqppmrxy3B_TnZIL886wQ1AC8enX8GEZhL_6krbVVkYTfHkz_Py2AGeeceR4xte5xNhzFQUOCv1UD7QkZzUsZu7RL4MD8WUDpPjC9rmsxTg4t8Fcd_Upw4PrWYM6alZdvswBxWroXPwgAqbU9cRzXfPro1

(END) Dow Jones Newswires

February 12, 2021 01:15 ET (06:15 GMT)